Novo Nordisk has entered an agreement to acquire Inversago Pharma for as much as $1.075 billion if certain development and commercial milestones are achieved. Inversago Pharma is a private, Montreal-based developer of CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders.   Inversago’s lead development asset INV-202, an oral CB1 inverse agonist is designed to preferentially block the receptor protein CB1 – which play...